Answers are grounded in this paper and cite their sources.
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a class of glucose-lowering medications that were recently approved for pediatric type 2 diabetes (T2D). A serious adverse effect of SGLT2i is euglycemic diabetic ketoacidosis (euDKA), a rare life-threatening metabolic emergency that was recognized after an increase in adult cases noted in postapproval safety surveillance programs. To our knowledge, SGLT2i-assoicated euDKA has not yet been described in youth with T2D since SGLT2i received pediatric approval in 2023. We report on a 17-year-old female patient with T2D on an SGLT2i who developed euDKA. She initially presented with vomiting that improved with antiemetics; however, she had persistent ketosis and developed significant acidosis, prompting diagnosis of euDKA. She was treated with intravenous insulin, dextrose-containing fluids, and electrolyte replacement with resolution of euDKA. This case highlights the challenges of recognizing SGLT2i-asosciated euDKA because of its rarity and the lack of hyperglycemia. As an increasing number of youth are started on SGLT2i, practitioners must be aware of the risk of SGLT2i-associated euDKA to allow for early recognition, adequate treatment, and prevention of serious complications.
No takes yet. Share an insight, caveat, or question.
Walker et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: